ST6GALNAC4 promotes immunosuppression through the T antigen-galectin 3+ TAM axis,[39] whereas HILPDA promotes HCC survival by inhibiting hypoxia-induced apoptosis.[40] ITGAM (an integrin family member) recruits immunosuppressive macrophages,[47] and P2RY6-expressing TAMs drive immune exclusion and therapy resistance.[48]. Here, HILPDA is linked to hepatocellular carcinoma.